Icon plc Stock
A loss of -2.860% shows a downward development for Icon plc.
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
As a result the target price of 203 € shows a positive potential of 27.19% compared to the current price of 159.6 € for Icon plc.
Pros and Cons of Icon plc in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Icon plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Icon plc | -2.860% | 0.063% | 12.039% | -19.353% | -22.336% | -18.571% | - |
| Alkermes plc | 0.810% | -0.794% | -7.407% | -14.384% | -10.714% | 2.690% | 60.256% |
| Ironwood Pharmaceuticals | 0.640% | -5.422% | 96.250% | -1.258% | -25.238% | -72.653% | -67.959% |
| Novocure Ltd | 2.370% | -6.222% | 2.868% | -58.648% | -64.286% | -86.012% | -91.451% |
Comments
Icon (NASDAQ:ICLR) was upgraded by analysts at Rothschild & Co Redburn from a "neutral" rating to a "buy" rating. They now have a $236.00 price target on the stock.
Show more
Ratings data for ICLR provided by MarketBeat
Icon (NASDAQ:ICLR) had its price target raised by analysts at Robert W. Baird from $222.00 to $224.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ICLR provided by MarketBeat
Icon Plc (NASDAQ: ICLR) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
Show more
Ratings data for ICLR provided by MarketBeat
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the
